Home PR Newswire
Monday, March 2, 2026
25.2
C
Bengaluru
Hot topics
Key Challenges Facing Indian Pharma
With the Second Wave hitting India, customers (patients and physicians) will continue to socially distance themselves in the foreseeable future. Pharma must use the field force for reach and relationship and digital for frequency and personalised content for better customer experience.
The pandemic has made doctors adopt Telehealth in a substantial way to shore up their revenues and this will continue to be one of their channels to engage patients. Telehealth along with EMR/EHR, digital therapeutics and wearables is enabling doctors to better care for their patients. There are many ways in which pharma can support the digital evolution of doctors.
Digital in Pharma and RoI – What and How to Measure Metrics that Matter
To be able to measure the RoI on digital in pharma, it is necessary to understand customers as individuals and create newer segmentation based on these needs and interests. This calls for the NextGen RCPA of data collection and personalized communications that engage customers, based on which pharma must create customer experiences that matter to them.
If your content does not scratch, where it itches the customers, digital or phygital, customers will not feel at home (comfortable, delighted, and wants more), which is what matters. Not a digital euphoria, which will soon die down as customers simply ignore it as they did when pharma launched a plethora of webinars.
Biologics Patent Cliff (2025–2029): A Golden Opportunity for Indian Pharma
https://www.pharmamanufacturing.com/articles/2011/095
A quiet but seismic shift is underway in global...
Indian Pharmaceutical Innovation – Post TRIPS
It is the twentieth anniversary of the new patent act in January 2025. The post-patent (P20) era is a story of resilience, determination, and charting a course that set global ambitions, a story of finding opportunity in adversity. It is a story for case studies in business schools, in international studies, in global health efforts.
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
Hot topics
Healthcare’s New Anti‑Fraud Playbook Will Reshape Hospitals, Pharma, Devices and Diagnostics
India’s AI‑enabled, anti‑FWA, interoperable roadmap is not a “payer‑only”...
3 Rules of the Digital World for Pharma Brand Managers
The first time I heard the term ‘digital economy’...
Key Highlights: Major Indian Pharma Companies – July 2025
Aurobindo Pharma Limited
Began sales to Europe through its China-based...
Medical Rep to Doctorate in Human Resources and Board of Directors
MVS Murthy
I began my career as a Medical Rep...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
India’s Pharma Renaissance: Private Equity at the Helm
Indian pharmaceuticals have long been known as the “pharmacy...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Levamisole Withdrawn in EU: Will India’s Regulator Follow?
On February 13, 2026, the Pharmacovigilance Risk Assessment Committee...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
Newsletter
Get important news delivered directly to your inbox and stay connected!